Dr. Swanson discusses a family-centered approach to treating mild-to-moderate atopic dermatitis in pediatric patients, emphasizing how age influences treatment selection, counseling, and shared decision-making. She highlights rapid improvement and tolerability as key priorities for children and families, particularly because burning and stinging can significantly affect treatment adherence in younger patients. Dr. Swanson also reviews topical ruxolitinib as a nonsteroidal option, discussing rapid itch relief, tolerability, and the importance of setting realistic expectations with families about the time required to achieve skin clearance.
